GLP-1s Cut Heart Attack Risk by 20%: The SELECT Trial Data Every Man Needs

If weight loss were the only benefit of GLP-1 medications, they'd still be revolutionary. But the SELECT trial may have revealed something even more important: semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 20% in people with obesity — even without diabetes.

The SELECT Trial

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a landmark randomized controlled trial. Key details:

• 17,604 participants with established cardiovascular disease and BMI ≥27, without type 2 diabetes
• Semaglutide 2.4mg weekly vs. placebo, mean follow-up ~40 months
• Primary endpoint: 20% reduction in MACE (major adverse cardiovascular events: CV death, non-fatal MI, non-fatal stroke)

This was the first trial to demonstrate that treating obesity with a GLP-1 reduces cardiovascular events independent of diabetes. It changed the clinical positioning of GLP-1 medications from "weight loss drugs" to "cardiovascular risk reducers."

Why Men Should Pay Attention

Cardiovascular disease is the #1 killer of American men. Men develop heart disease earlier than women (average first heart attack: age 65 for men vs. 72 for women). The combination of visceral obesity, hypertension, and dyslipidemia that's common in men over 40 is exactly the risk profile that SELECT addressed.

The SELECT population was 72% male. The cardiovascular benefit was consistent across sex, age, baseline BMI, and regional subgroups. This is as close to universally applicable data as cardiovascular medicine gets.

Beyond Weight Loss: The Mechanism

The cardiovascular benefit appears to be only partially explained by weight loss. GLP-1 receptor activation has direct effects on:

• Inflammation: Reduction in hsCRP (a systemic inflammation marker) — inflammation drives atherosclerosis
• Endothelial function: Improved blood vessel lining health
• Blood pressure: Modest but consistent reductions
• Lipid profile: Favorable shifts in triglycerides and inflammatory lipid markers

Kidney Protection Too

The FLOW trial added kidney protection to semaglutide's resume: 24% reduction in major kidney events, 20% reduction in all-cause death in patients with T2D and CKD. For men with both cardiovascular and kidney risk, semaglutide addresses two organ systems simultaneously.

If you have cardiovascular risk factors — even if you haven't had a cardiac event yet — the SELECT data suggests that GLP-1 therapy isn't just about looking better. It's about living longer.